At NINGBO INNO PHARMCHEM CO.,LTD., we recognize the profound impact that high-quality pharmaceutical intermediates have on global health. Gefitinib, identified by its CAS number 184475-35-2, is a prime example of such a critical compound. This pharmaceutical intermediate is fundamental to the synthesis of therapies designed to combat Non-Small Cell Lung Cancer (NSCLC), a challenging and widespread disease. Our commitment to excellence ensures that manufacturers have access to a reliable source for this vital molecule.

Gefitinib is distinguished by its efficacy as a protein kinase inhibitor. It specifically targets and deactivates certain tyrosine kinases, such as EGFR, which are often implicated in the uncontrolled growth of cancer cells. By blocking these key signaling pathways, Gefitinib provides a targeted treatment option that has significantly improved outcomes for patients with specific genetic profiles in their tumors. This precision medicine approach is a hallmark of modern oncology.

The chemical integrity of Gefitinib CAS 184475-35-2 is of utmost importance in its role as a pharmaceutical intermediate. Known also by its chemical name, N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, it has a molecular formula of C22H24ClFN4O3 and a molecular weight of 446.902. Supplied typically as a white to beige powder with a melting point of 119-120°C, consistency in these properties is vital for reproducible results in drug manufacturing. NINGBO INNO PHARMCHEM CO.,LTD. ensures rigorous quality assurance for our Gefitinib intermediate, guaranteeing it meets the stringent requirements of the pharmaceutical sector.

Understanding the clinical landscape for Gefitinib therapy includes awareness of potential side effects. While invaluable, treatment can lead to temporary increases in liver enzymes and, in rare cases, acute liver injury. This underscores the need for stringent quality control of the pharmaceutical intermediate used in its production and careful clinical management. Trusting suppliers like NINGBO INNO PHARMCHEM CO.,LTD. for Gefitinib pharmaceutical intermediate is essential to maintaining drug safety and efficacy.

In essence, Gefitinib CAS 184475-35-2 is a cornerstone in the development of advanced cancer treatments. Its role as a protein kinase inhibitor makes it indispensable for targeted NSCLC therapies. NINGBO INNO PHARMCHEM CO.,LTD. is proud to be a dependable supplier of this crucial pharmaceutical intermediate, contributing to the ongoing progress in cancer research and patient care. We are committed to supporting the pharmaceutical industry's mission to develop life-saving medications.